Personalized Cancer Therapy using Growth Hormone Receptor Antagonists

Publication ID: 24-11857602_0010_PTD

Published: October 28, 2025

Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Personalized Cancer Therapy using Growth Hormone Receptor Antagonists,” Published Technical Disclosure No. 24-11857602_0010_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857602_0010_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,602.

Summary of the Inventive Concept

A next-generation cancer treatment system utilizing growth hormone receptor antagonists tailored to individual patient profiles, enhancing treatment efficacy and minimizing side effects.

Background and Problem Solved

The original patent disclosed a composition for treating cancer using a human growth hormone receptor antagonist. However, it lacked personalization, resulting in variable treatment outcomes. This new inventive concept addresses this limitation by introducing a system that identifies a patient's specific growth hormone receptor expression profile, selects a customized combination of antagonist and chemotherapeutic drug, and administers the tailored treatment.

Detailed Description of the Inventive Concept

The system comprises three primary components: (1) a means for identifying a patient's specific growth hormone receptor expression profile, (2) a means for selecting a customized combination of a human growth hormone receptor antagonist and a chemotherapeutic drug based on the identified profile, and (3) a means for administering the customized combination to the patient. The modified antagonist features a polyethylene glycol molecule with a maleimide group for conjugation to a free sulfhydryl group, ensuring targeted delivery. The system also includes a monitoring component to track the patient's growth hormone receptor expression levels over time, enabling adjustments to the treatment regimen.

Novelty and Inventive Step

The new claims introduce a paradigm shift in cancer treatment by integrating personalized medicine with growth hormone receptor antagonists. The inventive concept's novelty lies in its ability to tailor treatment to individual patient profiles, whereas the original patent's composition was a one-size-fits-all approach.

Alternative Embodiments and Variations

Alternative embodiments may include varying the type of chemotherapeutic drug, using different methods for identifying patient profiles, or incorporating additional biomarkers to further personalize treatment. Variations may also involve adapting the system for treating other diseases responsive to human growth hormone receptor antagonists.

Potential Commercial Applications and Market

This inventive concept has significant commercial potential in the cancer treatment market, with potential applications in personalized medicine, targeted therapies, and companion diagnostics. The market for cancer treatment is projected to grow significantly in the coming years, driven by an increasing need for effective and personalized treatments.

CPC Classifications

Section	Class	Group
A	A61	A61K38/27
A	A61	A61K45/06
A	A61	A61K47/10
A	A61	A61P35/00
A	A61	A61K2039/505

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Biotechnology and pharmaceutical research, specifically cancer therapeutics and protein engineering, focusing on growth hormone receptor antagonists and personalized medicine approaches

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in molecular biology or biochemistry, experienced in protein modification, cancer treatment strategies, and drug development, with knowledge of receptor-based therapies and personalized medicine techniques

Obviousness Rationale

A person of ordinary skill would recognize that the PTD represents a predictable extension of the source patent's core technology by applying well-known personalization strategies to an existing growth hormone receptor antagonist. The modifications involve standard techniques in drug development, such as tailoring treatment based on receptor expression profiles and combining antagonists with chemotherapeutic drugs. These approaches are consistent with established personalized medicine principles and would be considered routine optimization by a skilled practitioner.

Obvious Combinations & Variations

Source Patent Element

Growth hormone receptor antagonist with specific amino acid substitutions

PTD Variation

Adding a personalized selection method based on individual patient's receptor expression profile

Obviousness Reasoning

Selecting drug treatments based on patient-specific biomarkers is a known technique in precision medicine, representing a predictable application of existing diagnostic approaches

Source Patent Element

Polyethylene glycol molecule with maleimide group for conjugation

PTD Variation

Integrating targeted delivery mechanism with patient-specific dosing strategy

Obviousness Reasoning

Combining drug delivery technologies with personalized dosing is a standard approach in pharmaceutical development, offering improved treatment efficacy through known modification techniques

Source Patent Element

Cancer treatment composition using growth hormone receptor antagonists

PTD Variation

Expanding treatment to multiple cancer types by dynamically adjusting antagonist dose based on ongoing receptor expression monitoring

Obviousness Reasoning

Adaptive treatment protocols are a predictable evolution in cancer therapy, representing a logical extension of existing personalized medicine principles

Source Patent Element

Specific cancer types treatable with growth hormone receptor antagonists

PTD Variation

Developing a systematic approach to identifying optimal patient candidates through comprehensive receptor expression analysis

Obviousness Reasoning

Patient stratification methods are a well-established technique in modern oncology, representing a standard approach to improving treatment selection

Source Patent Element

Combination therapy approach for cancer treatment

PTD Variation

Introducing dynamic monitoring and adjustment of treatment protocol based on patient-specific biomarker changes

Obviousness Reasoning

Continuous treatment monitoring and adjustment is a known strategy in precision medicine, representing a predictable refinement of existing therapeutic approaches

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857602, a person having ordinary skill in the art would find the personalized cancer therapy system and methods disclosed herein to be obvious variations of the prior art. The combination of known techniques in receptor antagonist development, personalized medicine, and cancer treatment strategies renders the claimed innovations obvious and anticipated under 35 U.S.C. Section 103, thereby establishing this disclosure as valid prior art against future patent claims in this technological domain.

Original Patent Information

Patent Number	US 11,857,602
Title	Growth hormone antagonist and anti-cancer composition combination therapy